The development and improvement of standardized reporting frameworks for various entities, including prostate cancer, such as PSMA-RADS version 2.0 and PROMISE V2, represents a substantial advancement in the field of medical imaging and clinical decision-making [26]. Here, FOLH1 is linked to prostate carcinoma.